학술논문
1229P - Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2018 29 Supplement 8
Subject
Language
ISSN
0923-7534